Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy.

Szczegóły
Abstrakt

Tytuł:: Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy.
Autorzy:: Vellichirammal NN; Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, NE, 68198, USA. Electronic address: .
Chaturvedi NK; Department of Pediatrics, Hematology, and Oncology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Joshi SS; Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Coulter DW; Department of Pediatrics, Hematology, and Oncology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Guda C; Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, NE, 68198, USA. Electronic address: .
Źródło:: Cancer letters [Cancer Lett] 2021 Feb 28; Vol. 499, pp. 24-38. Date of Electronic Publication: 2020 Nov 25.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
Język:: English
Imprint Name(s):: Publication: Limerick : Elsevier Science Ireland
Original Publication: Amsterdam, Elsevier/North-Holland.
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Biomarkers, Tumor/*genetics
Early Detection of Cancer/*methods
Neoplasms/*diagnosis
Oncogene Proteins, Fusion/*genetics
Antineoplastic Agents/pharmacology ; Biomarkers, Tumor/antagonists & inhibitors ; Biomarkers, Tumor/blood ; Child ; Circulating Tumor DNA/blood ; Circulating Tumor DNA/genetics ; Drug Monitoring/methods ; Genetic Testing/methods ; Genomics/methods ; High-Throughput Nucleotide Sequencing ; Humans ; Liquid Biopsy/methods ; Neoplasms/blood ; Neoplasms/drug therapy ; Neoplasms/genetics ; Oncogene Proteins, Fusion/antagonists & inhibitors ; Oncogene Proteins, Fusion/blood ; Precision Medicine/methods ; Treatment Outcome
References:: Nat Commun. 2019 Mar 27;10(1):1388. (PMID: 30918253)
Sci Rep. 2017 Mar 17;7:44653. (PMID: 28304380)
Cell Rep. 2018 Apr 3;23(1):227-238.e3. (PMID: 29617662)
Pediatr Blood Cancer. 2011 Oct;57(4):549-53. (PMID: 21442722)
Nature. 2013 Jul 11;499(7457):214-218. (PMID: 23770567)
Oncogene. 2005 Nov 17;24(51):7579-91. (PMID: 16044150)
Cancer Genet Cytogenet. 2003 Aug;145(1):1-30. (PMID: 12885459)
J Clin Oncol. 1996 Apr;14(4):1245-51. (PMID: 8648380)
Trends Cancer. 2016 Sep;2(9):475-484. (PMID: 28210711)
Int J Hematol. 2019 Apr;109(4):477-482. (PMID: 30689137)
Hereditas. 1972;67(1):89-102. (PMID: 4142006)
Oncogene. 1997 Mar 13;14(10):1159-64. (PMID: 9121764)
Clin Cancer Res. 2018 Aug 1;24(15):3528-3538. (PMID: 29776953)
Hum Genomics. 2016 Nov 18;10(1):36. (PMID: 27863505)
Lancet. 2017 Dec 9;390(10112):2569-2582. (PMID: 28890157)
J Clin Neurosci. 2012 Nov;19(11):1541-4. (PMID: 22981874)
Nat Genet. 2004 Apr;36(4):331-4. (PMID: 15054488)
JCO Precis Oncol. 2018;2018:. (PMID: 30027144)
Nature. 2008 May 1;453(7191):110-4. (PMID: 18408710)
N Engl J Med. 2013 Mar 28;368(13):1199-209. (PMID: 23484797)
Science. 1996 Jul 26;273(5274):494-7. (PMID: 8662537)
Arch Dis Child. 2003 Apr;88(4):354-7. (PMID: 12651771)
CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103. (PMID: 24488779)
J Clin Med. 2015 Jan 09;4(1):127-49. (PMID: 26237023)
Nat Rev Genet. 2014 Aug;15(8):556-70. (PMID: 25001846)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):373-378. (PMID: 29279377)
Mol Ther Nucleic Acids. 2020 Mar 6;19:1379-1398. (PMID: 32160708)
Adv Exp Med Biol. 2017;962:201-216. (PMID: 28299659)
PLoS Genet. 2015 Feb 06;11(2):e1005001. (PMID: 25658338)
Nat Immunol. 2007 May;8(5):463-70. (PMID: 17440452)
Blood. 2008 Dec 15;112(13):4808-17. (PMID: 19064740)
Blood. 1995 Jul 15;86(2):726-36. (PMID: 7606002)
Pediatr Blood Cancer. 2015 Apr;62(4):724-7. (PMID: 25382612)
Surg Clin North Am. 2006 Apr;86(2):469-87, xi. (PMID: 16580935)
Nat Genet. 1999 Oct;23(2):222-7. (PMID: 10508522)
Cancer Cell. 2012 Nov 13;22(5):683-97. (PMID: 23153540)
Nat Commun. 2017 Nov 6;8(1):1324. (PMID: 29109393)
Nature. 1994 Nov 10;372(6502):143-9. (PMID: 7969446)
Nature. 1973 Jun 1;243(5405):290-3. (PMID: 4126434)
Ann Diagn Pathol. 2018 Jun;34:1-12. (PMID: 29661713)
Oncogene. 2001 Sep 10;20(40):5736-46. (PMID: 11607823)
J Clin Oncol. 1998 Apr;16(4):1248-55. (PMID: 9552022)
Genome Res. 2012 Jul;22(7):1231-42. (PMID: 22588898)
Am J Surg Pathol. 2016 Feb;40(2):224-35. (PMID: 26501226)
Nucleic Acids Res. 2016 Jun 2;44(10):4487-503. (PMID: 27105842)
Pharmacol Res. 2017 Oct;124:74-91. (PMID: 28712971)
J Clin Oncol. 2007 Feb 1;25(4):370-5. (PMID: 17264332)
Surg Pathol Clin. 2019 Mar;12(1):165-190. (PMID: 30709442)
Crit Rev Oncog. 2006 Dec;12(3-4):257-71. (PMID: 17425505)
Gene. 2016 Sep 15;590(1):142-8. (PMID: 27317895)
Nat Genet. 2013 Mar;45(3):279-84. (PMID: 23334666)
Cell Rep. 2014 Apr 10;7(1):104-12. (PMID: 24703847)
Nat Genet. 2013 Aug;45(8):927-32. (PMID: 23817572)
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9530-5. (PMID: 21586637)
Leukemia. 2009 Jan;23(1):134-43. (PMID: 19020546)
Cancer Cell. 2012 Aug 14;22(2):153-66. (PMID: 22897847)
Lancet Oncol. 2017 Jun;18(6):719-731. (PMID: 28410997)
Blood. 2017 Mar 2;129(9):1113-1123. (PMID: 28115373)
Exp Hematol. 2010 Jan;38(1):3-10. (PMID: 19837128)
Cancer Res. 2009 Dec 1;69(23):9047-55. (PMID: 19920188)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
N Engl J Med. 1994 Aug 4;331(5):294-9. (PMID: 8022439)
Clin Cancer Res. 2018 Feb 15;24(4):939-949. (PMID: 29191970)
Acta Naturae. 2019 Apr-Jun;11(2):17-27. (PMID: 31413876)
Cancer. 2018 Nov 1;124(21):4241-4247. (PMID: 30204247)
J Exp Med. 2002 Jan 7;195(1):85-98. (PMID: 11781368)
Cell. 1994 Dec 2;79(5):885-92. (PMID: 8001125)
Cancer Genet Cytogenet. 1986 Jan 15;19(3-4):361-2. (PMID: 3943053)
J Mol Diagn. 2007 Sep;9(4):498-509. (PMID: 17690209)
Cancer Genet Cytogenet. 2003 Jul 15;144(2):91-9. (PMID: 12850370)
Am J Dis Child. 1972 Jun;123(6):561-4. (PMID: 4113489)
Sci Transl Med. 2018 Nov 7;10(466):. (PMID: 30404863)
Int J Biochem Cell Biol. 2014 Aug;53:493-504. (PMID: 24801613)
Leuk Res. 2011 May;35(5):585-90. (PMID: 21145591)
Virchows Arch. 2013 Dec;463(6):837-42. (PMID: 24213312)
Genes Chromosomes Cancer. 2012 Jul;51(7):662-74. (PMID: 22447499)
J Clin Oncol. 1998 Feb;16(2):527-35. (PMID: 9469337)
Nat Genet. 2017 Aug;49(8):1211-1218. (PMID: 28671688)
Sci Transl Med. 2015 Nov 11;7(313):313ra182. (PMID: 26560360)
Pediatr Blood Cancer. 2020 Jan;67(1):e28028. (PMID: 31595628)
Nucleic Acids Res. 2017 Jul 27;45(13):e120. (PMID: 28472320)
Proc Natl Acad Sci U S A. 2001 May 8;98(10):5776-9. (PMID: 11344311)
Nature. 1992 Sep 10;359(6391):162-5. (PMID: 1522903)
Am J Surg Pathol. 2020 May;44(5):607-616. (PMID: 32187044)
JCO Precis Oncol. 2017;2017:. (PMID: 29629425)
Am J Surg Pathol. 2016 Mar;40(3):386-94. (PMID: 26523541)
Mod Pathol. 2011 Mar;24(3):333-42. (PMID: 21113140)
Clin Cancer Res. 2013 Aug 1;19(15):4040-5. (PMID: 23719267)
Oncogene. 2012 Mar 22;31(12):1571-81. (PMID: 21860421)
Pediatr Blood Cancer. 2019 Aug;66(8):e27780. (PMID: 31034759)
Surg Clin North Am. 2008 Jun;88(3):615-27, vii. (PMID: 18514702)
Nature. 2017 Jul 19;547(7663):311-317. (PMID: 28726821)
Br J Cancer. 2018 Aug;119(5):615-621. (PMID: 30131550)
Molecules. 2018 Oct 28;23(11):. (PMID: 30373318)
Genome Med. 2015 Dec 18;7:129. (PMID: 26684754)
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8242-7. (PMID: 12048236)
Cancer Cell. 2015 May 11;27(5):728-43. (PMID: 25965575)
Cancer Res. 2017 Nov 1;77(21):5860-5872. (PMID: 29092923)
PLoS One. 2018 Apr 9;13(4):e0195272. (PMID: 29630678)
Pediatr Surg Int. 2013 Nov;29(11):1139-45. (PMID: 24022278)
Am J Surg Pathol. 1993 Mar;17(3):221-30. (PMID: 8434703)
Acta Neuropathol. 2015 Jun;129(6):775-88. (PMID: 25792358)
Blood. 1998 Feb 1;91(3):735-46. (PMID: 9446631)
Nat Commun. 2019 May 16;10(1):2198. (PMID: 31097696)
J Mol Evol. 2009 Jan;68(1):56-65. (PMID: 19089307)
Blood. 2009 Sep 3;114(10):2159-67. (PMID: 19589926)
Nature. 2018 Mar 15;555(7696):371-376. (PMID: 29489755)
N Engl J Med. 2018 Feb 22;378(8):731-739. (PMID: 29466156)
Cancer Res. 2006 Oct 15;66(20):9937-47. (PMID: 17047056)
Nature. 2012 Aug 2;488(7409):43-8. (PMID: 22722829)
Development. 1999 Nov;126(22):5073-84. (PMID: 10529424)
Nat Rev Cancer. 2013 Jun;13(6):397-411. (PMID: 23702928)
Nat Genet. 2012 May 29;44(6):619-22. (PMID: 22641210)
Genes Chromosomes Cancer. 2006 Aug;45(8):731-9. (PMID: 16646086)
Cell Mol Life Sci. 2018 Feb;75(3):417-446. (PMID: 28819864)
Blood. 2018 Sep 20;132(12):1241-1247. (PMID: 30049809)
Acta Neuropathol. 2012 Aug;124(2):247-57. (PMID: 22526017)
N Engl J Med. 2018 Nov 01;379(18):1754-1765. (PMID: 30380390)
Blood. 1997 Sep 1;90(5):1799-806. (PMID: 9292512)
Pediatr Int. 2018 Jan;60(1):41-46. (PMID: 29067751)
N Engl J Med. 2006 Jan 12;354(2):166-78. (PMID: 16407512)
J Clin Oncol. 2015 Sep 20;33(27):2938-48. (PMID: 26304874)
Chin J Cancer. 2013 Nov;32(11):594-603. (PMID: 24206917)
Bioinformatics. 2019 Jul 15;35(14):i225-i232. (PMID: 31510681)
Oncology. 1989;46(5):318-22. (PMID: 2779946)
BMC Cancer. 2014 Sep 05;14:654. (PMID: 25189734)
Nat Rev Dis Primers. 2018 Jul 5;4(1):5. (PMID: 29977059)
Lancet. 2008 Mar 22;371(9617):1030-43. (PMID: 18358930)
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5564-73. (PMID: 25512523)
J Neurooncol. 2018 May;138(1):29-39. (PMID: 29354850)
Neuro Oncol. 2015 Oct;17(10):1365-73. (PMID: 25795305)
Histopathology. 2018 Jan;72(2):320-329. (PMID: 28833375)
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100. (PMID: 31675094)
Oncogene. 2008 Oct 9;27(46):6034-43. (PMID: 18591936)
Nat Rev Cancer. 2015 Jun;15(6):371-81. (PMID: 25998716)
Cytogenet Cell Genet. 1987;45(3-4):148-55. (PMID: 3691179)
Oncotarget. 2016 Feb 2;7(5):5273-88. (PMID: 26672768)
Cancer Discov. 2015 Apr;5(4):380-95. (PMID: 25637275)
Adv Immunol. 2011;111:179-206. (PMID: 21970955)
Blood. 2016 May 19;127(20):2391-405. (PMID: 27069254)
Case Rep Pathol. 2020 Jan 30;2020:5903863. (PMID: 32082673)
Nat Rev Dis Primers. 2016 Nov 10;2:16078. (PMID: 27830764)
Nature. 2014 Feb 27;506(7489):451-5. (PMID: 24553141)
Oncogene. 2000 Aug 3;19(33):3799-804. (PMID: 10949935)
J Neurooncol. 2013 Nov;115(2):153-60. (PMID: 23925828)
Nat Rev Clin Oncol. 2019 Apr;16(4):227-240. (PMID: 30546053)
J Clin Oncol. 2012 Jul 20;30(21):2648-53. (PMID: 22665539)
Br J Haematol. 2009 Jan;144(2):147-56. (PMID: 19006567)
Clin Pharmacol Ther. 2020 Jan;107(1):176-180. (PMID: 31563145)
BMC Bioinformatics. 2013;14 Suppl 7:S2. (PMID: 23815381)
Genes Chromosomes Cancer. 2012 Mar;51(3):207-18. (PMID: 22072439)
Cancer Discov. 2015 Jan;5(1):25-34. (PMID: 25527197)
Nat Rev Cancer. 2003 Mar;3(3):203-16. (PMID: 12612655)
JAMA Oncol. 2018 May 1;4(5):717-721. (PMID: 29423503)
Nucleic Acids Res. 2016 Apr 7;44(6):2859-72. (PMID: 26837576)
Nature. 2018 Mar 15;555(7696):321-327. (PMID: 29489754)
Nat Commun. 2012 May 01;3:811. (PMID: 22549840)
Nat Genet. 2001 Jul;28(3):220-1. (PMID: 11431691)
J Clin Invest. 2012 Oct;122(10):3407-15. (PMID: 23023711)
Genes Chromosomes Cancer. 1991 Nov;3(6):480-2. (PMID: 1777415)
Blood. 2013 Oct 10;122(15):2704-13. (PMID: 23974201)
Nat Genet. 1998 Oct;20(2):207-11. (PMID: 9771718)
Blood. 1999 May 1;93(9):2760-70. (PMID: 10216069)
Genes Chromosomes Cancer. 2020 May;59(5):286-294. (PMID: 31756779)
Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):653-63. (PMID: 25834148)
Blood. 2010 Apr 15;115(15):3089-97. (PMID: 20160164)
Science. 2011 Jan 28;331(6016):435-9. (PMID: 21163964)
J Clin Oncol. 2010 Apr 20;28(12):1989-94. (PMID: 20308669)
JAMA Netw Open. 2019 Apr 5;2(4):e192906. (PMID: 31026031)
J Clin Oncol. 2015 Sep 20;33(27):3036-46. (PMID: 26304893)
Blood. 2006 Jul 1;108(1):28-37. (PMID: 16522812)
Blood. 1998 Jun 1;91(11):3995-4019. (PMID: 9596644)
Blood. 2020 Oct 15;136(16):1813-1823. (PMID: 32845001)
PLoS One. 2015 Dec 30;10(12):e0145754. (PMID: 26717006)
Genes Dis. 2019 Aug 30;6(4):385-390. (PMID: 31832518)
J Clin Oncol. 1994 May;12(5):925-30. (PMID: 8164043)
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. (PMID: 30333516)
Hemasphere. 2019 Jun 04;3(3):e250. (PMID: 31723839)
Cancer Med. 2019 Oct;8(14):6437-6448. (PMID: 31456361)
Blood. 2011 Sep 29;118(13):3645-56. (PMID: 21813447)
Eur Urol. 2016 Jun;69(6):1055-61. (PMID: 26433572)
Nat Rev Cancer. 2003 Sep;3(9):639-49. (PMID: 12951583)
N Engl J Med. 2000 Apr 6;342(14):998-1006. (PMID: 10749961)
Rev Clin Exp Hematol. 2002 Jun;6(2):91-113; discussion 200-2. (PMID: 12196211)
Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):E12295-E12304. (PMID: 30538195)
Hum Pathol. 2019 Apr;86:57-65. (PMID: 30633925)
Children (Basel). 2018 Aug 28;5(9):. (PMID: 30154341)
Clin Cancer Res. 2016 Sep 1;22(17):4356-65. (PMID: 27283964)
Haematologica. 2014 May;99(5):865-72. (PMID: 24441146)
Semin Cancer Biol. 1993 Dec;4(6):341-7. (PMID: 8142619)
Lancet Oncol. 2020 Apr;21(4):531-540. (PMID: 32105622)
J Child Neurol. 2016 Oct;31(12):1341-53. (PMID: 26336203)
Nat Rev Cancer. 2007 Apr;7(4):233-45. (PMID: 17361217)
J Clin Oncol. 2015 Sep 20;33(27):2949-62. (PMID: 26304895)
Oncotarget. 2016 Aug 23;7(34):55924-55938. (PMID: 27409839)
Ann Oncol. 2016 Sep;27 Suppl 3:iii4-iii15. (PMID: 27573755)
Clin Cancer Res. 2015 Jul 15;21(14):3196-203. (PMID: 25829397)
Cell. 2012 Jan 20;148(1-2):59-71. (PMID: 22265402)
Oncogene. 2009 Nov 19;28(46):4126-32. (PMID: 19718047)
Cell. 1994 Dec 2;79(5):875-84. (PMID: 8001124)
Semin Hematol. 2013 Oct;50(4):314-24. (PMID: 24246699)
Leukemia. 2018 Oct;32(10):2167-2177. (PMID: 29550834)
Nature. 1985 Jun 13-19;315(6020):550-4. (PMID: 2989692)
Cancer. 2016 Oct;122(19):3015-23. (PMID: 27351911)
Am J Surg Pathol. 2002 Dec;26(12):1553-66. (PMID: 12459622)
J Mol Diagn. 2018 Nov;20(6):765-776. (PMID: 30138724)
Nature. 2012 Aug 2;488(7409):49-56. (PMID: 22832581)
N Engl J Med. 2004 Apr 8;350(15):1535-48. (PMID: 15071128)
J Natl Cancer Inst. 1961 Nov;27:1013-35. (PMID: 14480645)
Nature. 2012 Jan 11;481(7380):157-63. (PMID: 22237106)
Grant Information:: P20 GM103427 United States GM NIGMS NIH HHS; P30 CA036727 United States CA NCI NIH HHS; P30 GM127200 United States GM NIGMS NIH HHS
Contributed Indexing:: Keywords: Fusion genes; Next-generation sequencing; Pediatric cancer; ctDNA
Substance Nomenclature:: 0 (Antineoplastic Agents)
0 (Biomarkers, Tumor)
0 (Circulating Tumor DNA)
0 (Oncogene Proteins, Fusion)
Entry Date(s):: Date Created: 20201128 Date Completed: 20210520 Latest Revision: 20220716
Update Code:: 20240105
PubMed Central ID:: PMC9275405
DOI:: 10.1016/j.canlet.2020.11.015
PMID:: 33248210
: Czasopismo naukowe

Full Text Finder

The incidence of pediatric cancers is rising steadily across the world, along with the challenges in understanding the molecular mechanisms and devising effective therapeutic strategies. Pediatric cancers are presented with diverse molecular characteristics and more distinct subtypes when compared to adult cancers. Recent studies on the genomic landscape of pediatric cancers using next-generation sequencing (NGS) approaches have redefined this field by providing better subtype characterization and novel actionable targets. Since early identification and personalized treatment strategies influence therapeutic outcomes, survival, and quality of life in pediatric cancer patients, the quest for actionable biomarkers is of great value in this field. Fusion genes that are prevalent and recurrent in several pediatric cancers are ideally suited in this context due to their disease-specific occurrence. In this review, we explore the current status of fusion genes in pediatric cancer subtypes and their use as biomarkers for diagnosis and personalized therapy. We discuss the technological advancements made in recent years in NGS sequencing and their impact on fusion detection algorithms that have revolutionized this field. Finally, we also discuss the advantages of pairing liquid biopsy protocols for fusion detection and their eventual use in diagnosis and treatment monitoring.
(Copyright © 2020. Published by Elsevier B.V.)

Informacja